In a Hypertension editorial commentary by Messerli and Staessen (Messerli FH, Staessen JA. Amlodipine better than lisinopril? How one randomized clinical trial ended fallacies from observational studies. Hypertension. 2006;48:359–361), the statement “considering the totality of outcome measures in ALLHAT, amlodipine appeared to have advantages over lisinopril” was based upon an earlier version of the paper by Leenen et al. (Leenen FHH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, Alderman MH, Atlas SA, Basile JN, Cuyjet AB, Dart R, Felicetta JV, Grimm RH, Haywood LJ, Jafri SZA, Proschan MA, Thadani U, Whelton PK, Wright JT; for the Antihypertensive and Lipid-Lowering Treatment toPrevent Heart Attack Trial (ALLHAT) Collaborative Research Group. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Hypertension. 2006;48:374–384.). However, this statement was not included in the accepted version of the paper Leenan et al.